Home › Funds › Spruce Street Capital LP › SABS
Spruce Street Capital LP position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Spruce Street Capital LP reported holding 2,198,502 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$7.0M, representing 1.11% of its reported portfolio and ranking #23 among its reported holdings. Spruce Street Capital LP has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's SABS position evolved
Spruce Street Capital LP first disclosed a stake in SABS in Q4 2025 at 2,198,502 shares (US$8.2M). The position peaked in Q2 2026 at 2,198,502 shares, worth US$8.6M. Across 4 filings, Spruce Street Capital LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,198,502 shares valued at US$7.0M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.20M | $8.22M | New |
| Q1 2026 | 2.20M | $8.42M | Hold |
| Q2 2026 | 2.20M | $8.57M | Hold |
| Q3 2026 | 2.20M | $6.97M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$21.9M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Vivo Capital, LLC 6.92M sh · $21.92M · Q3 2026
- Commodore Capital LP 2.87M sh · $11.19M · Q2 2026
- Sessa Capital IM, L.P. 2.20M sh · $8.57M · Q2 2026
- Sanofi 2.20M sh · $6.97M · Q3 2026
- Propel Bio Management, LLC 1.19M sh · $3.76M · Q3 2026
- Seven Fleet Capital Management LP 736.08K sh · $2.87M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held SABS?
Spruce Street Capital LP has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in SABS?
As of Q3 2026, Spruce Street Capital LP holds 2.20M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $6.97M, representing 1.11% of its reported portfolio and ranking #23.
Has Spruce Street Capital LP been buying or selling SABS?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in SABS. The position peaked in Q2 2026 at 2.20M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.